Halotestin Injectable (Fluoxymesterone)
An injectable preparation of fluoxymesterone (Halotestin), a fluorinated 17-alpha-alkylated testosterone derivative normally taken orally. It is one of the most androgenic-per-milligram steroids, prized by strength and combat athletes for aggression and strength without weight gain. Injecting the unesterified molecule does not lessen its notorious hepatotoxicity, and it remains a harsh, poorly characterised compound in injectable form.
01 Overview
Fluoxymesterone is a highly androgenic, non-aromatising oral steroid used clinically for hypogonadism and certain anemias and breast cancers. In performance use it is valued for sharp strength and aggression increases with minimal mass gain, making it popular before powerlifting meets or fights. The injectable form circulates rarely on the underground market.
Because fluoxymesterone keeps its 17-alpha-alkyl group, injection does not reduce its substantial liver toxicity, and its strongly negative lipid effects persist. Its clinical potency and toxicity are documented, but the injectable presentation specifically has no formal characterisation, so it should be treated as a harsh, high-risk compound used only in short bursts.
02 Mechanism
Fluoxymesterone is a potent, non-aromatising androgen receptor agonist; the fluorine and 17-alpha-alkyl substitutions increase potency and confer hepatotoxicity retained by injection.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Common | 70–140 mg/wk | IM | Roughly 10-20 mg/day equivalents; short pre-competition bursts. |
| High (harsh) | 140–280 mg/wk | IM | High doses sharply raise hepatic and cardiovascular risk. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Increased strength and aggressionFavoured for acute strength and drive without added bodyweight. | Pronounced strength boost | Observational | |
| Minimal weight gainUseful for athletes needing to stay within a weight class. | Low mass gain | Observational |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Aggression / mood disturbanceMarked irritability and aggression are a hallmark of this compound. | Moderate | Common | Observational | |
| HepatotoxicitySignificant liver enzyme elevation and cholestasis risk, documented clinically. | Severe | Common at cycle doses | Clinical | |
| Adverse lipid changesSteep HDL suppression raising cardiovascular risk. | Severe | Very common | Clinical |